Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Clinical Evident Portal Hypertension on Hepatocellular Carcinoma With Transarterial Chemoembolization (CHANCE-CHESS 2301): A Multicenter Retrospective Study

NCT05703750 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT05703750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05703750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Clinical Evident Portal Hypertension on Hepatocellular Carcinoma With Transarterial Chemoembolization (CHANCE-CHESS 2301): A Multicenter Retrospective Study
Lead sponsor
Zhongda Hospital
Phase
Observational
Overall status
Unknown status
Start date
May 4, 2023
Completion date
December 31, 2023
Enrollment
228 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, portal hypertension